



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Serial No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

# **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Supplemental Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on November 5, 2004

<u>Csaba Attila Szakolczai</u> (name of person mailing paper)

(signature of person mailing paper)



Attorney Docket No.: 6176.200-US **PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107 Group Art Unit: 1653

Filed: May 3, 2001 Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- 1. US 2003/0130191 A1
- 2. US 2003/0170863 A1
- 3. US 5,580,560
- 4. US 5,874,407
- 5. US 5,994,296
- 6. US 60/184,036
- 7. US 10/415,963
- 8. JP 2001 061479
- 9. JP 10/59866A
- 10. WO 88/10295
- 11. WO 94/07515
- 12. WO 94/27631
- 13. WO 97/20939
- 14. WO 98/31394
- 15. WO 01/58935 A2
- 16. WO 01/75086 A2
- 17. WO 01/82943 A2

11/09/2004 NRDCHA1 00000052 141447

180.00 DA

- 18. WO 01/83725 A1
- 19. WO 01/85198 A1
- 20. WO 02/22776 A2
- 21. WO 02/062376 A1
- 22. WO 02/077218 A1
- 23. WO 02/38162 A1
- 24. WO 03/027147 A2
- 25. Neuenschwander et al., Biochemistry, Vol. 34, pp. 8701-7 (1995)
- 26. Bernardi et al., Human Mutation, Vol. 8, pp. 108-15 (1996)
- 27. Chang et al., Biochemistry, Vol. 38, pp. 10940-48 (1999)
- 28. Leonard et al., Abstract 1474, Journ of Int Soc Thromb and Haemost., pg. 466 (Suppl. 08/99)
- 29. Iakhiev et al., Thromb and Haemost, Vol. 85 (3), pp. 458-63 (2001)
- 30. Jin et al., Journ of Mol Bio, Vol. 307 (part 5), pp. 1503-17
- 31. Persson et al., Journ of Biol Chem, Vol. 276 (31), pp. 29195-9 (2001)
- 32. International Search Report (08/25/2003)
- 33. International Search Report (02/05/2004)
- 34. Peyvandi et al., Throm Haemost, Vol. 84, pp. 250-7 (2000)
- 35. Peyvandi et al., Throm Haemost, Vol. 88, pp. 750-5 (2002)
- 36. Soejima et al., Jorun of Bio Chem, Vol. 276 (20), pp. 17229-35 (2001)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed after the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Date: November 5, 2004

Respectfully submitted,

Reza Green, Reg. No. 38,475

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540

(609) 987-5800

Please charge any additional fees, should they be required, to Novo Nordisk® Pharmaceuticals, Inc. Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449

GRE 2-32)

SUI

# U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Persson et al.

(Use several sheets if necessary)

Filing Date May 3, 2001

Group 1653

		II C DA'	TENT DOCUMENTS		1		
3	DOGUMENT	0.3.17	TENT DOCUMENTS			EII IN	DATE
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	2003/0130191 A1	10/28/02	Persson et al.				-
	2003/0170863 A1	05/03/01	Persson et al.				
	5,580,560	08/22/94	Nicolaisen et al.			-	
	5,874,407	09/17/97	Kelley et al.				. <u>.</u>
	5,994,296	03/05/98	Ruf et al.				<del></del>
	60/184,036	02/22/00					
		FOREIGN	PATENT DOCUMENTS				
	DOCUMENT					TRANSLATION	
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	2001 061479	08/24/99	JP				
	10/59866A	03/03/98	JP				
	88/10295	06/25/87	WO				
	94/07515	10/06/92	WO				
-	94/27631	05/23/94	WO				
	OTHER D	OCUMENTS (Includ	ling Author, Title, Date, Perti	nent Pages, Etc	.)		
			stry, Vol. 34, pp. 8701-7 (			·	
İ			Vol. 8, pp. 108-15 (1996)			-	
			8, pp. 10940-48 (1999)				
j			rn of Int Soc Thromb and	Haemost., p	g. 466 (Suppl.	08/99)	
						•	
			ost, Vol. 85 (3), pp. 458-6 io, Vol. 307 (part 5), pp.			<u> </u>	
	Persson et al., Jo	ourn of Biol Chem	, Vol. 276 (31), pp. 2919	5-9 (2001)			<u>-</u>
	International Se	arch Report (08/25	5/2003)				
	International Se	arch Report (02/0	5/2004)				_
	Peyvandi et al.,	Throm Haemost, \	Vol. 84, pp. 250-7 (2000)	)			
	Peyvandi et al.,	Throm Haemost, '	Vol. 88, pp. 750-5 (2002)	)			
	Soejima et al., J	orun of Bio Chem	, Vol. 276 (20), pp. 1722				
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

(C) (C) (C) (SUI

# U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Persson et al.

8.1	STATEMENT BY APPLICAN	Applicant 1 Croson Ct	Application of the second of t					
TOK E	(Use several sheets if necessary	Filing Date May 3, 20	Filing Date May 3, 2001 Group 1653					
A		U.S. PA	TENT DOCUMENTS					
EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
INITIAL	10/415,963	05/05/03	NAME Ruf et al.	CLASS	SUBCLASS	IF AFFRO	PRIATE	
		-		-				
		FOREIGN	PATENT DOCUMENTS		<del>r</del>	1		
	DOCUMENT					TRANSI	ATION	
	NUMBER 07/20020	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	97/20939	11/22/96						
	98/31394	01/20/98	WO					
	01/58935 A2	08/16/01	WO					
	01/75086 A2	10/11/01	WO					
	01/82943 A2	11/08/01	WO					
	OTTANA		I A d Will D A D				_	
	OTHER	DOCUMENTS (IIICIII	ding Author, Title, Date, Per	tinent rages, Etc	·9			
		**	20-					
			···					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

122)

SUPP

TRANSFINER

INITIAL

EXAMINER

# U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6176.200-US

Serial No. 09/848,107

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant Persson et al.

1 7004	(Use several sheets if necessary)	Filing Date May 3, 20	Filing Date May 3, 2001		Group 1653		
3/		U.S. PA	TENT DOCUMENTS			-	
BACKIINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	G DATE OPRIATE
		FOREIGN	PATENT DOCUMENTS				
	DOCUMENT					TRANS	LATION
	NUMBER 01/83725 A1	DATE 11/08/01	COUNTRY WO	CLASS	SUBCLASS	YES	NO
	01/85198 A1	11715/01	WO				
	02/22776 A2	03/21/02	WO			-	
	02/062376 A1	08/15/02	WO				1
	02/077218 A1	10/03/02	WO				
	OTHER D	OCUMENTS (Includ	ing Author, Title, Date, Per	tinent Pages, Etc	:.)		
İ							
İ							• -
							_

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Sheet 4 of 4 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ORM PTO-1449 Atty. Docket No. 6176.200-US Serial No. 09/848,107 SUPPLEMENTAL INFORMATION DISCLOSURE Applicant Persson et al. STATEMENT BY APPLICANT (Use several sheets if necessary) Filing Date May 3, 2001 Group 1653 U.S. PATENT DOCUMENTS EXAMINER DOCUMENT FILING DATE INITIAL NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATE FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE COUNTRY CLASS SUBCLASS YES NO NUMBER WO 05/16/02 02/38162 A1 WO 03/027147 A2 04/03/03 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

DATE CONSIDERED